Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: Results from the prospective, longitudinal, observational CoMMpass study Meeting Abstract
| Authors: | Landgren, O.; Siegel, D. S.; Auclair, D.; Chari, A.; Boedigheimer, M.; Welliver, T.; Mezzi, K.; Iskander, K.; Jakubowiak, A. |
| Abstract Title: | Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: Results from the prospective, longitudinal, observational CoMMpass study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837602177 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-112289 |
| Notes: | Meeting Abstract: 799 -- Source: Wos |
